HLAG anticorps

N° du produit ABIN192389

Détail du produit anti-HLAG anticorps

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLAG est non-conjugé

Application: ELISA, Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoprecipitation (IP)

Specificité: The mouse monoclonal antibody G233 recognizes an extracellular epitope on several isoforms of HLA-G expressed in all populations of extravillous trophoblast (cell columns, interstitial trophoblast, endovascular trophoblast, placental bed giant cells). HLA-G belongs to the nonclassical MHC Class I molecules (MHC Class Ib). The antibody G233 has been found not to cross-react with any other MHC Class I antigens (HLA-A, -B, -C, -E, -F).

Réactivité croisée (Details): Human

Purification: Purified by protein-A affinity chromatography.

Pureté: > 95 % (by SDS-PAGE)

Immunogène: HLA-A2.1/human beta2-microglobulin double transgenic mice were immunized with murine L cells transfected with both human beta2-microglobulin and HLA-G.

Clone: G233

Isotype: IgG2a

Information d'application

Indications d'application: Flow cytometry: Extracellular and intracellular staining, recommended dilution: 1-4 μg/mL.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Do not freeze.

Références pour anticorps anti-HLAG (ABIN192389)

Verloes, Van de Velde, Lemaoult, Mateizel, Cauffman, Horn, Carosella, Devroey, De Waele, Rebmann, Vercammen: "HLA-G Expression in Human Embryonic Stem Cells and Preimplantation Embryos." dans: Journal of immunology (Baltimore, Md. : 1950), (2011) (PubMed).

Gonzalez, Alegre, Arroyo, LeMaoult, Echeveste: "Identification of circulating nonclassic human leukocyte antigen G (HLA-G)-like molecules in exudates." dans: Clinical chemistry, Vol. 57, Issue 7, pp. 1013-22, (2011) (PubMed).

Van Lierop, Wijnands, Loke, Emmer, Lukassen, Braat, van der Meer, Mosselman, Joosten: "Detection of HLA-G by a specific sandwich ELISA using monoclonal antibodies G233 and 56B." dans: Molecular human reproduction, Vol. 8, Issue 8, pp. 776-84, (2002) (PubMed).

Blaschitz, Hutter, Dohr: "HLA Class I protein expression in the human placenta." dans: Early pregnancy (Online), Vol. 5, Issue 1, pp. 67-9, (2001) (PubMed).

Frumento, Franchello, Palmisano, Nicotra, Giacomini, Loke, Geraghty, Maio, Manzo, Natali, Ferrara: "Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment." dans: Tissue antigens, Vol. 56, Issue 1, pp. 30-7, (2000) (PubMed).

Rajagopalan, Long: "A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells." dans: The Journal of experimental medicine, Vol. 189, Issue 7, pp. 1093-100, (1999) (PubMed).

Mandelboim, Pazmany, Davis, Valés-Gómez, Reyburn, Rybalov, Strominger: "Multiple receptors for HLA-G on human natural killer cells." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, Issue 26, pp. 14666-70, (1998) (PubMed).

Loke, King, Burrows, Gardner, Bowen, Hiby, Howlett, Holmes, Jacobs: "Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody." dans: Tissue antigens, Vol. 50, Issue 2, pp. 135-46, (1997) (PubMed).

Détails sur HLAG

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Autre désignation: HLA-G (HLAG Produits)

Synonymes: anticorps MHC-G, anticorps B-F, anticorps B-F-S04, anticorps B-F-S05, anticorps B-F-S06, anticorps B-F-S07, anticorps B-FI, anticorps B-FIV, anticorps BF2, anticorps BFa2, anticorps BFw-03, anticorps BFw-05, anticorps BFz-01, anticorps major histocompatibility complex, class I, G, anticorps MHC BF1 class I, anticorps HLA-G, anticorps BF1

Sujet: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

ID gène: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints